ENSAIOS CLÍNICOS 2020

INVESTIGADOR PRINCIPAL	TÍTULO	FASE	EUDRACT	PROMOTOR
AMILOIDOSE | UNIDADE CORINO DE ANDRADE				
Ana Martins Silva	A Phase 1, Open-label, Dose Escalation Study of Intravenous PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis	I	2017-003521-15	Prothena Biosciences
Teresa Coelho	A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients With Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Patisiran Clinical Study	III	2014-003877-40	Alnylam Pharmaceuticals, Inc.
Teresa Coelho	An Open-label Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of Patisiran-LNP in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) With Disease Progression Post-Orthotopic Liver Transplant	III	2018-003519-24	Alnylam Pharmaceuticals, Inc.
Teresa Coelho	HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)	III	2018-002098-23	Alnylam Pharmaceuticals, Inc.

Teresa Coelho	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects With Symptomatic Transthyretin Amyloid Cardiomyopathy	III	2018-004280-32	Eidos Therapeutics, Inc.
Teresa Coelho	A phase 3, randomized, double-blind, placebo controlled multicenter study to evaluate the efficacy and safety of patisiran in patients with transthyretin mediated amyloidosis with cardiomyopathy	III	2019-001458-24	Alnylam Pharmaceuticals, Inc.
Teresa Coelho	A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy	III	2019-001698-10	Ionis Pharmaceuticals
Teresa Coelho	A phase 3, randomized, double-blind, placebo controlled, multicenter study to evaluate the eficacy and safety of vitrusiran in patients with transthyretin amyloidosis with cardiomyopathy (ATTR amyloidosis with cardiomyopathy)	II	2019-003153-28	Alnylam Pharmaceuticals, Inc.
CARDIOLOGIA				
Mário Santos	A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes POST Worsening Heart Failure	III	2017-003510-16	Sanofi

CIRURGIA VASCULAR				
Rui Almeida	An International, Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Thrombotic Vascular Events in Patients With Symptomatic Peripheral Artery Disease Undergoing Lower Extremity Revascularization Procedures Actual Study Start Date _ : August 18, 2015	III	2014-005569-58	Bayer
CUIDADOS INTENSIVOS				
Fernando Rua	Effects of Plasma Exchange With Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects With "Acute-On-Chronic Liver Failure" (ACLF) at High Risk of Hospital Mortality	III	2016-001787-10	Grifols
CUIDADOS INTENSIVOS NEONATAIS E PEDIÁTRICOS				
Elisa Proença	A Phase 2b, Multicenter, Randomized, Open-label, Controlled, 3-Arm Study to Evaluate the Clinical Efficacy and Safety of SHP607 in Preventing Chronic Lung Disease Through 12 Months Corrected Age Compared to Standard Neonatal Care in Extremely Premature Infants	II	2018-001393-16	Shire Inc
DERMATOLOGIA				
Inês Lobo	A Randomized, Double-blind, Multi-center Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa	III	2018-002063-26	Novartis

Inês Lobo	A Multicenter, double-blind, randomized withdrawal extension study of subcutaneous secukinumab to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe hidradenitis suppurative	III	2019-003230-17	Novartis
Inês Lobo	A randomized, double blind, placebo-controlled, multi-center, parallel group study to evaluate the efficacy and safety of dupilumab in patients with prurigo nodularis who are inadequately controlled on topical prescription therapies or when those therapies are not advisable	III	2019-003801-90	Sanofi
Tiago Torres	A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis	III	2016-003046-87	Abbvie
Tiago Torres	A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis	III	2018-001383-28	Abbvie
ENDOCRINOLOGIA				
Helena Cardoso	A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function	III	2017-002644-32	Sanofi

Helena Cardoso	Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity Who Have Reached Target Dose During run-in Period	III	2017-003473-34	NovoNordisk
Isabel Palma	A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke	III	2018-004565-14	Amgen
Rui Carvalho	A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate Efficacy and Safety of Finerenone on the Reduction of Cardiovascular Morbidity and Mortality in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease in Addition to Standard of Care	III	2015-000950-39	Bayer
GASTRENTEROLOGIA				
Daniela Ferreira	A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease	II	2017-002195-13	Janssen
Paula Lago	Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab	III	2016-002918-43	Janssen

Paula Lago	A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis	II	2018-004002-25	Janssen
GINECOLOGIA				
Hélder Ferreira	An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered With and Without Low-Dose Estradiol and Norethindrone Acetate in Women With Endometriosis-Associated Pain	III	2017-001588-19	Myovant Sciences GmbH
Hélder Ferreira	An International Phase 3 Open-Label, Single-Arm, Safety and Efficacy Extension Study to Evaluate Relugolix Co-Administered With Low-Dose Estradiol and Norethindrone Acetate in Women With Endometriosis-Associated Pain	III	2017-004066-10	Myovant Sciences GmbH
HEMATOLOGIA				
Cristina Gonçalves	A Multicenter, Single-arm, Open-label Study With Pomalidomide in Combination With Low Dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma	III	2012-001888-78	Celgene

Cristina Gonçalves	A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma	III	2014-000268-17	Celgene
Eugénia Cruz	A Phase 3, Open-label, Randomized, Multi-center, Controlled Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of Edoxaban and to Compare the Efficacy and Safety of Edoxaban With Standard of Care Anticoagulant Therapy in Pediatric Subjects From Birth to Less Than 18 Years of Age With Confirmed Venous Thromboembolism (VTE)	III	2016-000991-49	Daiichi-Sankyo
Jorge Coutinho	A Prospective, Randomized, Open Label, Two Arm Phase III Study to Evaluate Treatment Free Remission (TFR) Rate in Patients With Philadelphia-positive CML After Two Different Durations of Consolidation Treatment With Nilotinib 300mg BID	III	2012-005124-15	Novartis
Jorge Coutinho	A Randomized, Controlled, Double-Blind Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of GP2013 vs. MabThera® in Patients With Previously Untreated, Advanced Stage Follicular Lymphoma	III	2010-019522-13	Sandoz
Jorge Coutinho	A Phase 4, Open-label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma	IV	2012-004128-39	Millennium Pharmaceuticals

Jorge Coutinho	A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Continuation Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia	III	2015-004856-24	Daiichi-Sankyo
Jorge Coutinho	A Phase 2/3, Randomised, Multicentre Study of MOR208 With Bendamustine Versus Rituximab With Bendamustine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT)	II	2014-004689-11	Morphosis
Jorge Coutinho	A Phase III, Randomized, Double-blind, Controlled Multicenter Study of Intravenous PI3K Inhibitor Copanlisib in Combination With Standard Immunochemotherapy Versus Standard Immunochemotherapy in Patients With Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)	III	2015-001088-38	Bayer
Jorge Coutinho	A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab Versus Placebo in Combination With Rituximab in Treatment Naïve Subjects With Follicular Lymphoma	III	2016-003202-14	Pharmacyclics
INFECIOLOGIA				
Ana Horta	A Phase 3, Randomized, 2-Part Clinical Study in HIV-1-Infected Heavily Treatment Experienced Participants Evaluating the Antiretroviral Activity of Blinded MK-8591 and Doravirine Each Compared to Placebo (Part 1) and the Antiretroviral Activity, Safety, and Tolerability of Open-Label MK-8591A (Part 2)	III	2019-000588-26	Merck Sharp & Dohme

Rui Sarmento e Castro	A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults	III	2015-004418-95	Glaxo Smith Kline
Rui Sarmento e Castro	A phase IIb, randomized, controlled, dose-ranging study of oral GCK3640254 in combination with nucleoside reverse transcriptase inhibitors for induction of HIV-1 virologic suppression followed by na evaluation of maintenance of virologic suppression when oral GSK3640254 is combined with oral dolutegravir in HIV-1 infected, antiretroviral therapy-naive adults	II	2019-004435-23	ViiV
MEDICINA				
Abílio Reis	An open label, multicentre study to evaluate pharmacokinetics, safety and efficacy of zamicastat as adjunctive therapy in pulmonary arterial hypertension (PAH)	II	2018-002448-10	Bial
Abílio Reis	A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Group-sequential, Adaptive, Phase 3 Study With Open-label Extension Period to Assess the Efficacy and Safety of Selexipag as an add-on to Standard of Care Therapy in Subjects With Inoperable or Persistent/Recurrent After Surgical and/or Interventional Treatment Chronic Thromboembolic Pulmonary Hypertension	III	2018-002823-41	Janssen
Abílio Reis	A Multi-center, Double-blind, Placebo-controlled Phase 4 Study in Patients With Pulmonary Arterial Hypertension to Assess the Effect of Selexipag on Daily Life Physical Activity and Patient's Self-reported Symptoms and Their Impacts	IV	2017-000216-42	Actelion

Irene Marques	A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Trial to Evaluate the Efficacy and Safety of the Oral sGC stImulator Vericiguat to Improve Physical Functioning in Activities of Daily Living in Patients With Heart Failure and Preserved Ejection Fraction	II	2018-000298-65	Bayer
Irene Marques	A 24-week, Randomized, Double-blind, Multi-center, Parallel Group, Active Controlled Study to Evaluate the Effect of LCZ696 on NT-proBNP, Exercise Capacity, Symptoms and Safety Compared to Individualized Medical Management of Comorbidities in Patients With Heart Failure and Preserved Ejection Fraction	III	2016-003410-28	Novartis
Irene Marques	A Multicenter, Randomized, Parallel Group, Double Blind, Active and Placebo Controlled Study of BAY1753011, a Dual V1a/V2 Vasopressin Receptor Antagonist, in Patients With Congestive Heart Failure	II	2018-004059-18	Bayer
Irene Marques	A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy ans safety of finerenone on morbidiry and mortality in participants with heart failure (NIHA II-IV) and LVEF ≥ 40%	III	2020-000306-29	Bayer
João Neves	A Double-blind, Placebo-controlled, Multi-centre, Clinical Trial to Investigate the Efficacy and Safety of 12 Months of Therapy With Inhaled Colistimethate Sodium in the Treatment of Subjects With Non-cystic Fibrosis Bronchiectasis Chronically Infected With Pseudomonas Aeruginosa	III	2015-2743-33	Zanbom

NEFROLOGIA				
Idalina Beirão	A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate the Safety and Efficacy of Finerenone, in Addition to Standard of Care, on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease	III	2015-000990-11	Bayer
La Salete Martins	Randomised, Double-blind, Placebo-controlled (Within Dose Groups) and Active Controlled (Eplerenone Group) Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Oral Doses of BI 690517 Over 28 Days in Female and Male Patients With Diabetic Nephropathy	I	2017-000563-32	Boehringer Ingelheim
Sofia Santos	A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects With Metabolic Acidosis	III	2018-001303-36	TRICIDA
NEUROLOGIA				
Ana Martins Silva	Multicenter, Randomized, Double-blind, Parallel-group, Active-controlled, Superiority Study to Compare the Efficacy and Safety of Ponesimod to Teriflunomide in Subjects With Relapsing Multiple Sclerosis	III	2012-000540-10	Actelion

Ana Martins Silva	A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis Followed by Extended Treatment With Open-label BAF312	III	2012-003056-36	Novartis
Ana Martins Silva	A Multicenter, Open-Label Study Evaluating the Effectiveness of Oral Tecfidera™ (Dimethyl Fumarate) on MS Disease Activity and Patient-Reported Outcomes in Subjects With Relapsing-Remitting Multiple Sclerosis in the Real-World Setting	III	2013-001656-35	Biogen
Ana Martins Silva	A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis	III	2015-005419-33	Novartis
Ana Martins Silva	Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Portuguese Patients With Relapsing Remitting Multiple Sclerosis (MS) Transitioning From Current Subcutaneous Interferon Therapy to Peginterferon Beta 1a (PLEGRIDY™)	IV	2016-000434-21	Biogen
Ana Martins Silva	An Open-Label, Single-Arm Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Early Stage Relapsing Remitting Multiple Sclerosis	III	2016-002937-31	Roche

Ana Martins Silva	Multicenter, Non-comparative Extension to Study AC-058B301, to Investigate the Long-term Safety, Tolerability, and Control of Disease of Ponesimod 20 mg in Subjects With Relapsing Multiple Sclerosis	III	2016-004719-10	Actelion
Ana Martins Silva	A 2-Year Prospective Study to Assess Health-related Quality of Life In Subjects With Highly-Active Relapsing Multiple Sclerosis Treated With Mavenclad®	II	2017-002632-17	Merck
Ana Martins Silva	An Open-label, Single Arm, Multi-center Extension Study Evaluating Long-term Safety, Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis	III	2017-004703-51	Novartis
Ana Martins Silva	A Phase IIIb, randomized, double-blind, placebocontrolled, parallel-group, multicenter study to evaluate efficacy of upper limb function and safety of ocrelizumab	III	2018-001511-73	Roche
Ana Martins Silva	A single-arm, prospective, multicenter, open-label study to evaluate ofatumumab treatment effectiveness and patient-reported outcomes in patients with relapsing multiple sclerosis transitioning from dimethyl fumarate or fingolimod therapy to ofatumumab	III	2019-001341-40	Novartis

Carlos Andrade	A 12-month Prospective, Randomized, Interventional, Global, Multi-center, Activecontrolled Study Comparing Sustained Benefit of Two Treatment Paradigms (Erenumab qm vs. Oral Prophylactics) in Adult Episodic Migraine Patients	IV	2018-001228-20	Novartis
Ernestina Santos	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis	III	2018-003243-39	Alexion
OFTALMOLOGIA				
Bernardete Pessoa	A Two-year, Three-arm, Randomized, Double-masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Diabetic Macular Edema	III	2017-004742-23	Novartis
Miguel Lume	A 64-week, Two-arm, Randomized, Double-masked, Multicenter, Phase IIIb Study Assessing the Efficacy and Safety of Brolucizumab 6 mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen in Patients With Neovascular Agerelated Macular Degeneration	III	2019-000716-28	Novartis
Ricardo Parreira	Open-label, randomized, two–arm, controlled study to assess the efficacy, safety, and tolerability of intravitreal (IVT) aflibercept compared to laser photocoagulation in patients with retinopathy of prematurity (ROP)	III	2018-002611-99	Bayer

Ricardo Parreira	An extension study to evaluate the long term outcomes of subjects who received treatment for retinopathy of prematurity in study 20090	III	2018-003180-54	Bayer
ONCOLOGIA				
António Araújo	A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) Versus Platinum Based Chemotherapy in Treatment Naïve Subjects With PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer	III	2014-001473-14	MERCK
António Araújo	A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer	III	2014-003207-30	Roche
António Araújo	A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel or Atezolizumab in Combination With Carboplatin+Nab-Paclitaxel Versus Carboplatin+Nab-Paclitaxel in Chemotherapy-Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer	III	2014-003208-59	Roche
António Araújo	A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+ Non-small Cell Lung Cancer	III	2015-001537-24	MERCK

António Araújo	Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus Cyclophosphamide, Doxorubicin and Vincristine (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line	III	2015-001641-89	Pharma Mar
António Araújo	A Randomized, Phase 3 Trial With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) Versus Placebo for Patients With Early Stage NSCLC After Resection and Completion of Standard Adjuvant Therapy	III	2015-000575-27	MERCK
António Araújo	A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma	III	2016-004359-57 †	Boston Biomedical
António Araújo	A Randomized, Open-Label (Formerly Double-Blind), Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination With Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment	II	2016-002778-11	Eisai
António Araújo	A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects With Extensive Stage Small Cell Lung Cancer	III	2016-003503-64	Abbvie

António Araújo	A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma	III	2018-000519-26	Astellas
António Araújo	A Phase 3 Randomized, Double-Blind, Controlled Study Evaluating Bemarituzumab (FPA144) and Modified FOLFOX6 in Patients With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 3 Preceded by Dose-Finding in Phase 1	III	2017-003507-22	Five Prime Therapeutics, Inc.
António Araújo	A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab (MEDI4736) Alone or in Combination With Novel Agents in Subjects With Locally Advanced, Unresectable (Stage III) Non-small Cell Lung Cancer	II	2018-002931-35	MedImmune
António Araújo	An Open-label, Randomised, Phase III Study cOmparing trifLuridine/Tipiracil (S 95005) in Combination With Bevacizumab to Capecitabine in Combination With Bevacizumab in firST-line Treatment of Patients With metastatIC Colorectal Cancer Who Are Not candidatE for Intensive Therapy	III	2017-004059-22 †	Servier
António Araújo	Randomized, Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated Non Squamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors	III	2019-001273-81	Sanofi

António Araújo	A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 Versus Platinum-Based Chemotherapy as First-Line Treatment in Patients With NSCLC With EGFR Exon 20 Insertion Mutations	III	2019-001845-42	Millennium Pharmaceuticals
António Araújo	Phase III, randomized, open-label, controlled study to evaluate the efficacy, safety and pharmacokinetics of atezolizumab in combination with cabozantinib compared with docetaxel monotherapy in patients with metastatic non-small cell lung cancer previously treated with an immune checkpoint inhibitor and platinum-based chemotherapy	III	2020-000100-011	Roche
Joana Febra	A Phase III Randomized Trial of MK-3475 (Pembrolizumab) Versus Standard Treatment in Subjects With Recurrent or Metastatic Head and Neck Cancer	III	2014-001749-26	MERCK
Joana Febra	A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination With Tremelimumab Versus Standard of Care Chemotherapy in Patients With Unresectable Stage IV Urothelial Cancer	III	2015-001633-24	Astra Zeneca
Joana Febra	A randomized double-blind phase 3 study of avelumab in combination with standard of care chemoradiotherapy (cisplatin plus definitive radiation therapy) versus standard of care chemoradiotherapy in the front-line treatment of patients with locally advanced squamous cell carcinoma of the head and neck	III	2016-001456-21	Pfizer

Joana Febra	A Randomized, Open Label, Multicenter Phase 2/3 Study to Evaluate the Efficacy and Safety of Rogaratinib (BAY1163877) Compared to Chemotherapy in Patients With FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma Who Have Received Prior Platinum-containing Chemotherapy	II	2016-004340-11	Bayer
Joana Febra	A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer	III	2017-003364-12	Janssen
Joana Febra	A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of Talazoparib With Enzalutamide In Metastatic Castration-resistant Prostate Cancer	III	2017-003295-31	Pfizer
Joana Febra	A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK-3475) in Combination with Transarterial Chemoembolization (TACE) Versus TACE in Participants with Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012)	III	2019-002345-37	Merck Sharp & Dohme
Joana Febra	A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer	III	2020-000348-77	Exelixis, Inc.

Noémia Afonso	Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma	II	2015-002801-12 †	Cascadian Therapeutics
Noémia Afonso	An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease	III	2016-003467-19	Novartis
Noémia Afonso	Phase 2 Study of MCLA-128-based Combinations in Metastatic Breast Cancer (MBC): MCLA-128/ Trastuzumab/Chemotherapy in HER2-positive MBC and MCLA-128/Endocrine Therapy in Estrogen Receptor Positive and Low HER2 Expression MBC	II	2017-002821-39	Merus
Noémia Afonso	A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer	III	2016-004362-26	Lilly
Noémia Afonso	A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-related Genes (including BRCA1/2)	II	2017-002361-22	Astra Zeneca

Noémia Afonso	A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (KEYNOTE-756)	III	2017-003507-22	Merck Sharp & Dohme
Noémia Afonso	A Multi-centre, Double-blind, Placebo-controlled, Randomised Phase II Trial to Compare Efficacy of Xentuzumab in Combination With Everolimus and Exemestane Versus Everolimus and Exemestane in Women With HR+ / HER2- Metastatic Breast Cancer and Non-visceral Disease	II	2017-003131-11	Boehringer Ingelheim
Noémia Afonso	Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive (Human Epidermal Receptor) Breast Cancer: FDG-PET Response-adapted Strategy	II	2016-002676-27 †	MedSIR
Noémia Afonso	A Phase 3, Multicenter, Randomized, Open-label, Active Controlled Trial of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice for HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects	III	2018-003069-33	Daiichi-Sankyo
Noémia Afonso	A Phase III, Double-blind, Placebo-controlled, Randomized Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer	III	2019-000810-12	Roche

Noémia Afonso	Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial	III	2018-002990-24	Radius Pharmaceuticals, Inc.
Noémia Afonso	A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of GDC 0077 plus palbociclib and fulvestrant versus placebo plus palbociclib and fulvestrant in patients with locally advanced or metastatic pik3ca-mutant hormone receptor-positive, her2 negative breast cancer	III	2019-002455-42	Roche
Noémia Afonso	A phase III, randomised, double-blind, placebo-controlled, multicentre study of the efficacy and safety of atezolizumab plus chemotherapy for patients with early relapsing recurrent (inoperable locally advanced or metastatic) triple-negative breast cancer	III	2016-005119-42	Roche
Paula Fidalgo	A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of previously treated Locally Advanced and unresectable or Metastatic NSCLC Subjects with Mutated KRAS p.G12C	III	2019-003582-18	Amgen
Sérgio Azevedo	A phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab (anti-TIGIT antibody) in patients with locally advanced esophageal squamous cell carcinoma	III	2020-001178-31	Roche

Sílvia Lopes	Phase III Randomized Sequential Open-label Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer	III	2018-000347-60 †	Grupo de Tratamiento de los Tumores Digestivos (TTD)
Sílvia Lopes	A Phase 3 Randomized Placebo-controlled Double blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving FOLFOX-based Chemotherapy for Treatment of Gastrointestinal or Colorectal Cancer	III	2017-002992-25	Amgen
ORTOPEDIA				
Adélio Vilaça	A Randomized, Open-Label, Study Drug-Dose Blind, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-70033093 (BMS-986177), an Oral Factor XIa Inhibitor, Versus Subcutaneous Enoxaparin in Subjects Undergoing Elective Total Knee Replacement Surgery	II	2018-004237-32	Janssen
PEDIATRIA				
Caldas Afonso	Phase 3, Single-arm, Open-label, Multidose, Titration, Pharmacokinetic, Pharmacodynamic, and Safety Study of Etelcalcetide in Children and Adolescents 2 to < 18 Years of age With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis	III	2018-004608-21	Amgen

Emília Costa	A Phase II, Open-label, Non-controlled, Intra-patient Dose-escalation Study to Characterize the Pharmacokinetics After Oral Administration of Eltrombopag in Pediatric Patients With Refractory, Relapsed or Treatment Naive Severe Aplastic Anemia or Recurrent Aplastic Anemia	II	2015-003166-91	Novartis
Laura Marques	A Two-arm, Phase 2/3 Multicentre, Open-label, Randomised Study Evaluating Safety and Antiviral Effect of Current Standard Antiretroviral Therapy Compared to Once Daily Integrase Inhibitor Administered With Darunavir/ Ritonavir (DRV/r) in HIV-1 Infected, Virologically Suppressed Paediatric Participants	III	2013-001476-37 †	Pediatric European Network for Treatment of AIDS
Laura Marques	An open-label, multi-centre, randomised (1:1), non-inferiority, Phase II/III, 96-week, 2-arm clinical trial to compare the efficacy and toxicity of DTG plus 2 NRTI vs. standard of care (SOC) in HIV-infected children aged less than 18 years who are starting first-line ART (ODYSSEY A) or switching to second-line ART (ODYSSEY B)	III	2014-002632-14 †	Pediatric European Network for Treatment of AIDS
Manuel Magalhães	A double blind, randomised, placebo-controlled trial to evaluate the dose-exposure and safety of nintedanib per os for 24 weeks, followed by open label treatment with nintedanib of variable duration, in children and adolescents (6 to 17 year-old) with clinically significant fibrosing Interstitial Lung Disease	III	2018-004530-14	Boehringer Ingelheim
Teresa Temudo	A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 as an Adjunctive Therapy in Pediatric Patients With Developmental and/or Epileptic Encephalopathies	II	2018-002485-39	Ovid Therapeutics

UNIDADE DE IMUNOLOGIA CLÍNICA				
Ana Campar	A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab	III	2011-005667-25	Human Genome Sciences
António Marinho	A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Rheumatoid Arthritis	III	2012-003686-17	Lilly
António Marinho	A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis	III	2015-004477-32	Novartis
António Marinho	Study of Safety and Efficacy of Multiple VAY736 Doses in Patients With Moderate to Severe Primary Sjogren's Syndrome (pSS)	II	2016-003292-22	Novartis
António Marinho	A phase IIb, double-blind, randomized, placebo-controlled, multicenter, dose-ranging study to evaluate the efficacy and safety profile of PF-06700841 in participants with active systemic lupus erythematosus (SLE)	II	2018-004175-12	Pfizer

António Marinho	A Phase III randomized, double-blind, placebo controlled parallel-group, multicenter study of subcutaneous secukinumab 300mg added onto Standard of Care to demonstrate the efficacy at 52 weeks and to assess the long term efficacy, safety and tolerability up to 2 years in patients with Active ISN/RPS class III or IV Lupus Nephritis	III	2019-003211-57	Novartis
António Marinho	A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy	II	2019-000328-16	Amgen
Carlos Vasconcelos	Rituximab for Lupus Nephritis With Remission as a Goal, an Investigator-initiated Randomized International Open Multicentric Study	III	NCT01673295 †	Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Bruxelles, Belgium
UROLOGIA				
Miguel Ramos	A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men with Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)	III	2018-003135-30	Urovant
Miguel Ramos	A randomized, placebo-controlled, double-blind, parallel-group, multi-center, proof-of-concept study to assess the efficacy and safety of BAY 1817080 in patients with overactive bladder (OAB) over a 12-week treatment period	II	2019-002575-34	Bayer

Legenda: † Ensaios da iniciativa do investigador